BioWorld Asia

April 7, 2004

Australia-Based Norwood Seeks IPO On London's AIM Exchange

An Australian company with a U.S. development partner is expecting to float on the Alternative Investment Market in London to raise £15 million (US$27.2 million). (BioWorld International) Read More

Ablynx Completes EUR25M Series B Financing For Nanobody Platform

HIV Research Could Benefit From Immune System Model

Cilian, Evotec Neuroscience Reel In Venture Funding Totaling EUR30M

Ardana Signs New Zentaris Deal, Gains Global Rights To Teverelix

EU Finalizes Environmental Law That Could Leave Biotech Liable

Gastrotech Acquires Lilly Deal Through Purchase Of IP Assets

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...